Related Experiment Video
Updated: Jun 18, 2026

An Immature Murine Model of Reversible Unilateral Ureteral Obstruction
Published on: April 4, 2025
Exploring precision risk in pediatric vesicoureteral reflux: Innate immune gene variations and reflux outcomes in the
Jin Kyu Kim1, Rosalia Misseri1, Joshua Roth1
1Department of Urology, Riley Hospital for Children, United States.
Insights
Genetic variations in innate immune genes like DEFA1A3 influence urinary tract infection outcomes in children with vesicoureteral reflux (VUR). High DEFA1A3 copy number improved VUR, while DMBT1 interacted with prophylaxis for resolution.
Area of Science:
- Genetics
- Immunology
- Pediatrics
Background:
- Children with vesicoureteral reflux (VUR) face increased risks from recurrent urinary tract infections (UTIs).
- Factors influencing spontaneous VUR resolution are not well understood.
- This study investigates genetic variations in urinary innate immune genes (DEFA1A3, DMBT1, RNASE7) and their impact on VUR resolution and response to prophylaxis.
Purpose of the Study:
- To evaluate if genetic variations in DEFA1A3, DMBT1, and RNASE7 influence VUR resolution in children.
- To determine if these genetic variations interact with prophylactic treatment to alter clinical outcomes.
- To identify potential genetic biomarkers for predicting VUR outcomes.
Main Methods:
- Secondary analysis of 303 RIVUR participants with DEFA1A3 and DMBT1 copy number variation (CNV) and RNASE7 genotype data.
- Primary outcomes assessed were VUR improvement (grade decrease) and VUR resolution.
- Multivariable logistic regression models were used, adjusting for clinical covariates and including genotype-treatment interactions. Internal validation employed bootstrapping.
Main Results:
- Higher DEFA1A3 copy number (>5) was significantly associated with increased odds of VUR improvement (OR 2.36, p=0.023).
- High-grade VUR was linked to lower odds of resolution (OR 0.34, p=0.038).
- A significant interaction between DMBT1 copy number and prophylaxis was observed for VUR resolution (interaction OR 2.99, p=0.031). RNASE7 genotype showed no association.
Conclusions:
- Innate immune gene variations may explain the heterogeneity in VUR outcomes.
- High DEFA1A3 copy number is linked to reflux improvement, and DMBT1 interacts with prophylaxis for resolution.
- These findings are hypothesis-generating, suggesting potential genotype-based benefits from prophylaxis or a more favorable natural history.
Introduction:
Children with vesicoureteral reflux (VUR) are at increased risk for morbidity from recurrent urinary tract infections (UTIs), yet the factors influencing spontaneous VUR resolution remain poorly defined. This study evaluates whether genetic variations in key urinary innate immune effectors (DEFA1A3, DMBT1, and RNASE7) influences VUR resolution and interacts with prophylaxis to alter clinical response.
Methods:
We conducted a secondary analysis of 303 RIVUR participants with available DEFA1A3 and DMBT1 copy number variation (CNV) data and RNASE7 rs1263872 genotype. Primary outcomes were (1) VUR improvement (decrease in grade) and (2) VUR resolution at study exit. Multivariable logistic regression models included genotype, treatment, and their interactions, adjusting for age, sex, baseline grade (high vs low), laterality, bowel/bladder dysfunction, and any UTI. Internal validation used 2000-sample bootstrap with bias-corrected and accelerated confidence intervals and influence diagnostics.
Results:
Clinical covariates did not significantly predict VUR improvement. Children with DEFA1A3 CNV >5 had higher odds of improvement (OR 2.36, 95% CI 1.12-4.96, p = 0.023), an effect that remained significant in bootstrap analyses. High-grade VUR was associated with lower odds of resolution (OR 0.34, 95% CI 0.12-0.94, p = 0.038). A significant interaction was observed between prophylaxis and high DMBT1 copy number for VUR resolution (interaction OR 2.99, 95% CI 1.11-8.04, p = 0.031); no interaction was seen for improvement. RNASE7 rs1263872 was not associated with either outcome.
Conclusion:
Innate immune gene variation may contribute to heterogeneity in VUR outcomes. High DEFA1A3 copy number was associated with reflux improvement and a DMBT1-prophylaxis interaction was associated with reflux resolution. The results of this study is hypothesis-generating and prompt further evaluation to assess whether a subset of children may experience structural benefit from prophylaxis or have a more favorable natural history based on their innate immune genotype.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Respiratory Syncytial Virus Disease
Urinary Tract Infection II: Pathophysiology
Imaging Studies V: Intravenous Urography and Retrograde Pyelography